Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. BioNexus Gene Lab's Total Liabilities for the quarter that ended in Jun. 2026 was $0.95 Mil. BioNexus Gene Lab's Total Assets for the quarter that ended in Jun. 2026 was $8.73 Mil.
Therefore, BioNexus Gene Lab's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.11.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
BioNexus Gene Lab Liabilities-to-Assets Related Terms
BioNexus Gene Lab Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs CNEY, SNES, QGAI: Liabilities-to-Assets Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Liabilities-to-Assets vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
BioNexus Gene Lab's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Liabilities-to-Assets of 0.11 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's Liabilities-to-Assets too high?
BioNexus Gene Lab's current Liabilities-to-Assets is 0.11. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Liabilities-to-Assets compare to CNEY and SNES?
BioNexus Gene Lab's Liabilities-to-Assets of 0.11 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Chemicals company?
A good Liabilities-to-Assets depends on the Chemicals industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Liabilities-to-Assets is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.55 — trading 24% above its estimated fair value. The current Liabilities-to-Assets is 0.11. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Liabilities-to-Assets is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.55 is trading 24% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Liabilities-to-Assets: 0.11
GF Value™: $1.25 vs. price of $1.55 (24% above fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
